Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel, Blood, vol.129, issue.4, pp.424-447, 2017. ,
Genetic and epigenetic determinants of AML pathogenesis, Semin Hematol, vol.56, issue.2, pp.84-93, 2019. ,
Curative strategies in APL, Semin Hematol, vol.56, issue.2, pp.131-139, 2019. ,
Acute myeloid leukemia: Epidemiology and etiology, Cancer, vol.107, issue.9, pp.2099-107, 2006. ,
Cancer incidence in France over the 1980-2012 period: Hematological malignancies, Rev Epidemiol Sante Publique, vol.64, issue.2, pp.103-112, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01511580
Acute Myeloid Leukemia, N Engl J Med, issue.373, pp.1136-52, 2015. ,
Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B, Blood, vol.58, issue.6, pp.1203-1212, 1981. ,
How I treat acute myeloid leukemia, Blood, vol.116, issue.17, pp.3147-3156, 2010. ,
Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group, J Clin Oncol, vol.27, issue.1, pp.61-70, 2009. ,
An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation, Haematologica, vol.101, issue.11, pp.1351-1359, 2016. ,
Allogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy, Bone Marrow Transplant, vol.52, issue.8, pp.1083-90, 2017. ,
Risks and benefits in a personalized application of allogeneic transplantation in patients with AML in first CR, Semin Hematol, vol.56, issue.2, pp.164-70, 2019. ,
Should patients with acute myeloid leukemia and measurable residual disease be transplanted in first complete remission?, Curr Opin Hematol, vol.2017, issue.24, pp.132-138 ,
Treatment of murine leukaemia with x rays and homologous bone marrow, Br Med J, vol.2, issue.4993, p.626, 1956. ,
Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy, N Engl J Med, vol.257, issue.11, pp.491-96, 1957. ,
Optimal Threshold and Time of Absolute Lymphocyte Count Assessment for Outcome Prediction after Bone Marrow Transplantation, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, vol.22, issue.3, pp.505-518, 2016. ,
From genetic single candidate gene studies to complex genomics of GvHD, Br J Haematol, vol.178, issue.5, pp.661-675, 2017. ,
Peripheral Blood or Bone Marrow Stem Cells? Practical Considerations in Hematopoietic Stem Cell Transplantation, Transfus Med Rev, 2018. ,
Acute and Chronic Graft-Versus-Host Disease After Allogeneic Peripheral-Blood Stem-Cell and Bone Marrow Transplantation: A Meta-Analysis, J Clin Oncol, vol.19, issue.16, pp.3685-91, 2001. ,
Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, vol.15, issue.11, pp.1431-1439, 2009. ,
Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome, J Clin Oncol Off J Am Soc Clin Oncol, vol.23, issue.24, pp.5675-87, 2005. ,
Sequential Conditioning with Thiotepa in T Cell-Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, vol.24, issue.5, pp.1013-1034, 2018. ,
EBMT?NIH?CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment, Bone Marrow Transplant, vol.53, issue.11, p.1401, 2018. ,
Classification systems for chronic graft-versus-host disease, Blood, vol.129, issue.1, pp.30-37, 201705. ,
Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy, Blood, vol.80, issue.4, pp.1090-1093, 1992. ,
Hematopoietic Stem-Cell Transplantation for Acute Leukemia in Relapse or Primary Induction Failure, J Clin Oncol, vol.28, issue.23, pp.3730-3738, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-00849640
Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Bone Marrow Transplant, vol.52, pp.955-61, 2017. ,
Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood, vol.108, pp.3280-3288, 2006. ,
Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT, J Hematol OncolJ Hematol Oncol, vol.10, issue.1, pp.130-140, 2017. ,
Allogeneic hematopoietic cell transplantation with reduced-intensity conditioning following FLAMSA for primary refractory or relapsed acute myeloid leukemia, Ann Hematol, vol.92, issue.10, pp.1389-95, 2013. ,
Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia, Leukemia, vol.25, issue.5, pp.808-821, 2011. ,
Immune reconstitution after allogeneic hematopoietic stem cell transplantation, Front Immunol, vol.7, p.507, 2016. ,
Rapid recovery of CD3+ CD8+ T cells on day 90 predicts superior survival after unmanipulated haploidentical blood and marrow transplantation, PloS One, vol.11, issue.6, p.156777, 2016. ,
Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE Trial, Biol Blood Marrow Transplant, vol.23, issue.9, pp.1491-1498, 2017. ,
Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A CIBMTR® Study, Biol Blood Marrow Transplant, vol.21, issue.8, pp.1479-1487, 2015. ,
Allogeneic stem cell transplantation for refractory acute myeloid leukemia: a single center analysis of long-term outcome, Eur J Haematol, vol.95, issue.6, pp.498-506, 2015. ,
Impact of pretransplant leukemic blast% in bone marrow and peripheral blood on transplantation outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation in non-CR, Bone Marrow Transplant, vol.53, issue.4, pp.478-82, 2018. ,
Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation, Blood, vol.108, issue.3, pp.1092-1101, 2006. ,
Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysis, Lancet Haematol, vol.2, issue.9, pp.384-92, 2015. ,
Refractory AML -The transplanter's perspective. European Society for Blood and Marrow Transplantation, 2019. ,
Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome, Biol Blood Marrow Transplant, vol.23, issue.10, pp.1736-1779, 2017. ,
Efficacy of haploidentical hematopoietic stem cell transplantation compared to HLA-matched transplantation for primary refractory acute myeloid leukemia, Ann Hematol, vol.97, issue.11, pp.2185-94, 2018. ,
Haploidentical Transplants for Acute Myeloid Leukemia in Adults. Haploidentical Transplantation, Advances and Controversies in Hematopoietic Transplantation and Cell Therapy, vol.2018, pp.231-243 ,
Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT, Haematologica, vol.104, issue.3, pp.524-556, 2019. ,
Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation, J Cancer Res Clin Oncol, vol.142, issue.1, pp.317-341, 2016. ,
Early tapering of immunosuppressive agents after HLA-matched donor transplantation can improve the survival of patients with advanced acute myeloid leukemia, Ann Hematol, vol.97, issue.3, pp.497-507, 2018. ,
Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia, Haematologica, vol.101, issue.7, pp.879-83, 2016. ,
Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia -a matched pair analysis by the Acute Leukaemia Working Party of EBMT, Br J Haematol, vol.184, issue.5, pp.782-789, 2019. ,
A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia, Biol Blood Marrow Transplant, vol.19, issue.7, pp.1040-1045, 2013. ,
New drugs creating new challenges in acute myeloid leukemia, Genes Chromosomes Cancer, vol.1, pp.1-12, 2019. ,
Treatment of relapsed/refractory acute myeloid leukemia, Curr Treat Options Oncol, vol.18, issue.3, p.17, 2017. ,
Will CAR T cell therapy have a role in AML? Promises and pitfalls, Semin Hematol, vol.56, issue.2, pp.155-63, 2019. ,